Skip to main content
OpenTrials
Completed

NCT Number: NCT03949335

Clinical Investigation of the Safety and Effectiveness of an Investigational Model of the TECNIS® Intraocular Lens

This study will be a prospective, multicenter, bilateral, comparative, three-way masked (Sponsor, subject and evaluator), randomized clinical investigation conducted at up to 15 sites. Up to 300 subjects will be enrolled to achieve approximately 270 bilaterally implanted subjects, resulting in approximately 244 evaluable subjects (122 per lens group) at 6 months. After informed consent is obtained and confirmation that all eligibility criteria are met, the eye(s) may be treated according to randomization.

After signing the informed consent form, subjects meeting all eligibility criteria will be randomized in a masked fashion to a treatment group: either the investigational IOL Model ZFR00V or the control IOL Model ZCB00. Prior to randomization, the investigator will choose which eye to operate on first for each subject at his/her discretion based on his/her standard clinical practice (e.g., the eye with the worse cataract, poorer best corrected distance vision and/or more severe optical/visual complaints). All subjects are intended to have bilateral cataract surgery with the second eye surgery occurring after the 1-week postoperative exam for the first eye, but no more than 30 days after the first eye surgery. All subjects will be examined through 6 months postoperatively according to the visit schedule

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Empire Eye & Laser Center, Bakersfield, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • be at least 22 years old
  • have cataracts in both eyes
  • sign the written informed consent
  • be willing and able to comply with examination procedures
  • understand, read and write English to complete informed consent and questionnaires
  • be available for study follow-up visits

Exclusion criteria

  • currently participating in any other clinical study or have participated in a clinical study during the last 60 days
  • have a certain disease/illness such as poorly-controlled diabetes
  • have certain ocular conditions such as uncontrolled glaucoma
  • Is taking medication that may affect vision
  • Subject is pregnant, plan to become pregnant during the study, or is breastfeeding

Treatment and study plan

IOL Model ZFR00V

Device

Bilateral implantation with Investigational IOL Model ZFR00V

IOL Model ZCB00

Device

Bilateral Implantation with control IOL Model ZCB00

Primary outcomes

  1. Distance-Corrected Near Visual Acuity (DCNVA) at 40 cm

    Time frame: 6 months (postoperative)

    mean photopic monocular Distance Corrected Near Visual Acuity results at 40 cm for ZFR00 and control first eyes in the safety population at 6 months

Secondary outcomes

  1. Monocular Distance-Corrected Intermediate Visual Acuity at 66 cm

    Time frame: 6 months (postoperative)

    mean photopic monocular Distance-Corrected Intermediate Visual Acuity results at 6 months for ZFR00 and control first eyes in the safety population

  2. Monocular Distance-Corrected Near Visual Acuity at 33 cm

    Time frame: 6 months postoperative

    mean photopic monocular Distance-Corrected Near Visual Acuity results at 33 cm for ZFR00 and control first eyes in the safety population at 6 months

  3. Monocular Photopic Best-Corrected Distance Visual Acuity

    Time frame: 6 months postoperative

    mean monocular Best-Corrected Distance Visual Acuity results at 6 months for ZFR00 and control first eyes in the safety population.

  4. Monocular Distance-Corrected Defocus Curve

    Time frame: 6 months postoperative

    Mean monocular (first eye) distance-corrected defocus curve for each lens group at 6 months in the safety population

  5. Spectacle Wear

    Time frame: 6 months postoperative

    Spectacle wear is determined via the PRO questionnaire instrument and defined as wearing glasses or contacts "none of the time" in all 4 conditions (distance vision, intermediate vision, near vision and overall vision) at 6 months postoperative.

Sponsors and collaborators

Lead sponsor

Johnson & Johnson Surgical Vision, Inc.

Industry

Registry information

Acronym: BRAVO

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
May 14, 2019
Registry last updated
Aug 27, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.